RxSight (RXST) Q2 2026 earnings review
Core Business Stumbles, Masked by Alcon Lifeline
RxSight's preliminary Q2 results reveal a severe deceleration in its core business, obscured only by a timely strategic collaboration with Alcon. The underlying metrics are alarming: LAL unit volumes dropped sequentially to 24,917, and capital equipment placements (LDDs) collapsed to just 11 units. Management cited 'widespread competitive trialing' as the culprit, directly contradicting their Q1 assertion that new competitor lenses would have only a 'transient impact.' Consequently, FY26 core product sales guidance was slashed. However, the Alcon partnership injects $30-$40 million in high-margin FY26 revenue, which structurally improves the P&L and allowed management to raise total revenue and gross margin guidance despite the core operational miss.
🐂 Bull Case
The strategic collaboration validates the Light Adjustable Technology platform while injecting $30-$40M of highly accretive revenue in FY26. This fundamentally de-risks the balance sheet and funds necessary commercial investments.
Total gross margin guidance was raised to 73%-75% from 70%-72%. This neutralizes previous concerns about higher-cost 2025 inventory flowing through the P&L, largely due to the high-margin nature of the new royalty stream.
🐻 Bear Case
LAL volumes fell ~9% sequentially to 24,917 units. This shatters the Q1 narrative that procedure volumes had 'stabilized' and exposes deep vulnerability to new fixed-IOL competitors.
Placing only 11 LDDs in the quarter (down from 83 a year ago and 20 in Q1) means the expansion of the addressable market has effectively stalled, capping future recurring revenue potential.
⚖️ Verdict: 🔴
Bearish on core operations, Neutral overall. The Alcon deal provides an incredible financial parachute, but investors must recognize that the foundational utilization thesis is currently failing under competitive pressure.
Key Themes
Competitive Trialing Crushes Core Volume
The most troubling data point is the sequential drop in LAL units to 24,917 (down from 27,472 in 26Q1). Management explicitly blamed 'meaningful commercial headwinds' and 'widespread competitive trialing.' This severely contradicts the Q1 narrative, where the CEO dismissed new premium lenses from J&J and BVI as 'not a lot new under the sun' and claimed utilization had 'stabilized.' The data shows competition is winning share.
Alcon Strategic Collaboration
This partnership is a structural pivot. By collaborating with Alcon to develop light-adjustable Presbyopia-Correcting IOLs, RxSight adds $5-$7M in immediate Q2 revenue and $30-$40M for FY26. It transforms RxSight from a pure-play hardware/consumables company into a platform licensor, securing a high-margin cash stream that entirely masks the top-line miss in product sales.
Capital Equipment Collapse
LDD placements fell to a dismal 11 units. For context, the company placed 83 units in 25Q1 and 20 units in 26Q1. While management has framed lower LDD sales as a 'strategic pivot' toward utilization, an absolute number this low suggests practices have frozen capital purchases, starving the future installed base necessary for long-term LAL growth.
Accelerating Next-Generation Pipeline
To combat competitive pressure, RxSight is pushing its Light Adjustable Technology platform forward. The pipeline highlights intermediate-term launches of the next-generation LAL+ (improving intermediate vision) and LAL Toric (built-in astigmatism correction). These innovations, which promise improved workflow and fewer required post-operative treatments, are critical to re-engaging surgeons who are currently trialing competitor lenses.
Core Product Guidance Cut
Despite the overall top-line guidance raise, management quietly slashed FY26 core product sales guidance to $110-$120M (from $120-$135M). This $12.5M midpoint reduction proves that the fundamental 'utilization over placement' strategy is heavily missing its targets.
Gross Margin Resilience
Total gross margin guidance was upgraded to 73%-75% (from 70%-72%). While this is almost certainly an artifact of adding $30-$40M of near-100% margin Alcon revenue to the mix, the mathematical result is that the company will successfully absorb the drag of higher-cost 2025 inventory without compressing the overall corporate margin profile.
Other KPIs
Accelerating overall, but only due to the Alcon collaboration. Q1 revenue was $30.9M, meaning core product sales ($27M) actually declined sequentially by ~$3.9M. The $6M midpoint collaboration revenue provided the beat.
Stable. Dropped only slightly from $218.6M in Q1. This balance sheet strength is critical as management guides to the high end of operating expenses ($150-$160M) to fund emergency 'accelerating investments' in the commercial sales force.
Guidance
Accelerating vs prior guidance of $120-$135M. However, the entire raise is attributable to the new $30-$40M Alcon agreement, effectively acting as a bailout for the core business miss.
Decelerating. Lowered from the previous $120-$135M range. This validates the bear case that practice re-engagement programs are failing to counteract the pull of new competitor IOLs.
Accelerating from previous 70%-72% guidance. This reflects the favorable mix shift injected by the strategic collaboration revenue.
Stable. Reiterated at the high end of the range as the company scrambles to deepen penetration and defend market share via expanded LAL sales force initiatives.
Key Questions
Margin Mix Reality
How much of the FY26 gross margin upgrade to 73-75% is purely mathematically driven by the Alcon collaboration revenue, and what is the standalone margin profile of the core product business given the lower volume?
Capital Equipment Floor
With LDD placements down to just 11 units this quarter, have we reached the absolute floor for capital purchases, or are practices freezing budgets entirely while they trial new premium IOLs?
Competitive Narrative Shift
In Q1, you described competitor launches as having a 'transient impact.' Given the $12.5 million midpoint cut to core product sales guidance, has your structural view on the competitiveness of the LAL changed?
Alcon Collaboration Mechanics
Can you elaborate on the mechanics of the $30-$40M recognized from Alcon this year? Are these upfront milestones, and what is the trajectory for this revenue stream into 2027?